{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T22:10:44Z","timestamp":1741731044166,"version":"3.38.0"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pre\u2010exposure prophylaxis with tixagevimab\u2010cilgavimab significantly reduced severe COVID\u201019 outcomes in high\u2010risk individuals during the pre\u2010Omicron era (PROVENT trial). However, efficacy in patients with haematological malignancies (HM) was underreported. The rapid emergence of Omicron strains in 2021 showed reduced neutralizing activity in preclinical data, but real\u2010world data remains limited due to short follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>We aimed to evaluate the effectiveness and safety of tixagevimab\u2010cilgavimab in 86 HM patients during the early Omicron wave, including the BA.2, BA.5, and XBB.1 sublineages.<\/jats:p><jats:p>These patients received PrEP between February and August 2022 due to impaired vaccine response (72%) and B\u2010cell depletion (46.5%). They were followed prospectively until April 2023, with a median follow\u2010up of 297\u2009days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Breakthrough SARS\u2010CoV\u20102 infections occurred in 32.6% of patients, with 22.1% within six months. Infections within six months were milder and shorter. B\u2010cell depletion within six (<jats:italic>p<\/jats:italic>\u2009=\u20090.035) and twelve months (<jats:italic>p<\/jats:italic>\u2009=\u20090.016) was identified as risk factor for breakthrough infections. No new safety events were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our data showed that tixagevimab\u2010cilgavimab prophylaxis effectively reduces severe COVID\u201019 outcomes in patients with HM, particularly within the first six months, even during the Omicron era. However, those with recent B\u2010cell depletion (within 12\u2009months) remained at high risk.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14377","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T08:21:01Z","timestamp":1736151661000},"page":"690-699","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SARS\u2010COV\u20102 Pre\u2010Exposure Prophylaxis With Tixagevimab\u2010Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era"],"prefix":"10.1111","volume":"114","author":[{"given":"Manuela A.","family":"Hoechstetter","sequence":"first","affiliation":[{"name":"Department of Haematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine Muenchen Klinik Schwabing  Munich Germany"},{"name":"Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), LMU University Hospital Ludwig\u2010Maximilians University  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva\u2010Maria","family":"Hollwich","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine Muenchen Klinik Schwabing  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Illner","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine Muenchen Klinik Schwabing  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thu\u2010Trang","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine Muenchen Klinik Schwabing  Munich Germany"},{"name":"Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), LMU University Hospital Ludwig\u2010Maximilians University  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"von Bergwelt\u2010Baildon","sequence":"additional","affiliation":[{"name":"Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), LMU University Hospital Ludwig\u2010Maximilians University  Munich Germany"},{"name":"German Cancer Consortium (DKTK), partner Site Munich A Partnership Between the DKFZ Heidelberg and the University Hospital of the LMU  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), LMU University Hospital Ludwig\u2010Maximilians University  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens\u2010Martin","family":"Wendtner","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine Muenchen Klinik Schwabing  Munich Germany"},{"name":"Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), LMU University Hospital Ludwig\u2010Maximilians University  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010021\u201001177\u20100"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100747"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2023-0171"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab353"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011568"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01270-w"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100198"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00170-9"},{"issue":"7","key":"e_1_2_9_10_1","article-title":"COVID\u201019 in Patients Receiving CD20\u2010Depleting Immunochemotherapy for B\u2010Cell Lymphoma","volume":"5","author":"Gaitzsch E.","year":"2021","journal-title":"Hema"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2020.11.011"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl8124"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2023.2170348"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116620"},{"key":"e_1_2_9_15_1","unstructured":"FDA \u201cFact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld 2023 \u201daccessed November 27 2023 https:\/\/www.fda.gov\/media\/154701\/download."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01731-1"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-08559-5"},{"key":"e_1_2_9_18_1","unstructured":"\u201cFDA Announces Evusheld is not Currently Authorized for Emergency use in the U.S. \u201dhttps:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010announces\u2010evusheld\u2010not\u2010currently\u2010authorized\u2010emergency\u2010use\u2010us."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018283"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.05.007"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.07.015"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17121"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.14740\/jh1062"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107042"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05671-6"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004629"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008445"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211049737"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01549-x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.2598"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26626"},{"issue":"3","key":"e_1_2_9_32_1","article-title":"Risk Factors and Mortality of COVID\u201019 in Patients With Lymphoma: A Multicenter Study","volume":"5","author":"Regalado\u2010Artamendi I.","year":"2021","journal-title":"Hema"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605221127520"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.07.008"},{"issue":"10","key":"e_1_2_9_35_1","first-page":"458","article-title":"Safety and Immunogenicity of Cilgavimab\u2010Tixagevimab for COVID\u201019 Pre\u2010Exposure Prophylaxis in Immunocompromised Patients","volume":"160","author":"Fern\u00e1ndez\u2010Prada M.","year":"2023","journal-title":"Medicina Cl\u00ednica"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T21:42:40Z","timestamp":1741729360000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/ejh.14377"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14377","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"2024-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}